True Sub-Micron Ocular Diagnostics with Visible Light Optical Coherence Tomography

使用可见光光学相干断层扫描进行真正的亚微米眼部诊断

基本信息

批准号：
10212395
负责人：
Vivek Jay Srinivasan
金额：
$ 58.65万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-08-01 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10212395
关键词：
Accounting Age Age related macular degeneration Aging Anatomy Atrophic Benchmarking Biological Markers Blindness Bruch&apos s basal membrane structure Classification Clinical Clinical Research Clinical Trials Clinical Trials Design Communities Complex Cone Data Densitometry Deposition Diagnosis Diagnostic Drusen Elderly Ethnic Origin Eye Fiber Fundus Goals Histopathology Human Image Imaging technology In Vitro Individual Intervention Trial Light Longitudinal Studies Macular degeneration Maps Measurement Measures Melanins Melanosomes Modality Modeling Molecular Morphology Mus Nonexudative age-related macular degeneration Optical Coherence Tomography Optics Pathology Photoreceptors Pigmentation physiologic function Play Protocols documentation Reproducibility Resolution Rest Retina Retinal Diseases Retinal Pigments Risk Risk Factors Rodent Role Scanning Sensitivity and Specificity Severities Shapes Specificity Structure Structure of retinal pigment epithelium System Technology Testing Thick Time Validation Visible Radiation Vision Work adaptive optics age related attenuation base candidate marker chromophore clinical imaging cohort data acquisition density early detection biomarkers effective therapy end stage disease experimental study geographic atrophy imaging capabilities imaging study improved in vivo in vivo imaging innovation instrument instrumentation morphometry new technology predictive marker progression marker retinal imaging specific biomarkers submicron

Accounting Age Age related macular degeneration Aging Anatomy Atrophic Benchmarking Biological Markers Blindness Bruch&apos s basal membrane structure Classification Clinical Clinical Research Clinical Trials Clinical Trials Design Communities Complex Cone Data Densitometry Deposition Diagnosis Diagnostic Drusen Elderly Ethnic Origin Eye Fiber Fundus Goals Histopathology Human Image Imaging technology In Vitro Individual Intervention Trial Light Longitudinal Studies Macular degeneration Maps Measurement Measures Melanins Melanosomes Modality Modeling Molecular Morphology Mus Nonexudative age-related macular degeneration Optical Coherence Tomography Optics Pathology Photoreceptors Pigmentation physiologic function Play Protocols documentation Reproducibility Resolution Rest Retina Retinal Diseases Retinal Pigments Risk Risk Factors Rodent Role Scanning Sensitivity and Specificity Severities Shapes Specificity Structure Structure of retinal pigment epithelium System Technology Testing Thick Time Validation Visible Radiation Vision Work adaptive optics age related attenuation base candidate marker chromophore clinical imaging cohort data acquisition density early detection biomarkers effective therapy end stage disease experimental study geographic atrophy imaging capabilities imaging study improved in vivo in vivo imaging innovation instrument instrumentation morphometry new technology predictive marker progression marker retinal imaging specific biomarkers submicron

展开

项目摘要

Abstract: Optical Coherence Tomography (OCT) has greatly advanced the diagnosis and management of many retinal diseases by enabling volumetric structural imaging of the retina. Usually, retinal OCT is performed at near- infrared (NIR) wavelengths, limiting both axial resolution and contrast for molecules that play a role in vision. Though NIR OCT defines biomarkers that quantify progression of dry age-related macular degeneration (AMD), NIR OCT cannot yet delineate the finest structural and functional changes that define incipient AMD, or predict geographic atrophy, an end stage of AMD. Visible light OCT holds the promise of unprecedented axial resolution and molecular contrast, but visible light OCT systems to date have not delivered on this promise. Recently, our group identified numerous technical barriers, some unknown to the community, in visible light OCT. With our innovative solutions, we can now directly image and individually quantify Bruch’s membrane, the retinal pigment epithelium (RPE), and fine photoreceptor layers in morphologically normal retina without clinically detectable pathology, at a level of detail not attained by NIR OCT systems. These imaging capabilities are further enhanced by quantitative molecular information provided by visible light. In this proposal, we will develop fiber-based visible light OCT instrumentation and protocols to assess sub-micron changes with aging and macular degeneration in human eyes. Employing a range of in vitro and in vivo studies in rodents and humans, we propose to validate protocols that topographically measure the outer retina, RPE, and BM morphology, photopigment and melanin density, and photoreceptor function. We will validate and test the reproducibility of these structural and functional measurements, and apply them to study age-related changes in a cross-section of normal subjects. Finally, we will perform pilot clinical imaging studies to firstly, compare aging to early AMD, and secondly, identify candidate early biomarkers for progression of drusen to atrophy. If successful, this proposal will lay the groundwork for more extended longitudinal studies to study AMD progression in the human retina, and incorporation of new biomarkers into clinical trials.

抽象的：光学相干断层扫描（OCT）大大提高了许多视网膜的诊断和管理通过启用视网膜的体积结构成像来疾病。通常，视网膜OCT在接近红外（NIR）波长，限制了在视觉中发挥作用的分子的轴向分辨率和对比度。尽管NIR OCT定义了量化干燥年龄相关黄斑变性（AMD）进展的生物标志物，但 NIR OCT还不能描述定义初期AMD或预测的最佳结构和功能变化地理萎缩，AMD的结束阶段。可见光OCT具有前所未有的轴向分辨率的承诺和分子对比，但迄今为止可见的光OCT系统尚未在这一承诺上传递。最近，我们的小组在可见光的OCT中确定了许多技术障碍，有些是社区未知的。有了我们的创新解决方案，我们现在可以直接形象并单独量化Bruch的膜，其余的颜料上皮（RPE）和形态正常视网膜中的细光感受器层，没有临床可检测的病理学，在NIR OCT系统未附加的细节上。这些成像功能是通过可见光提供的定量分子信息进一步增强。在此提案中，我们将开发基于光纤的可见光OCT仪器和协议来评估子微调随着人眼中的衰老和黄斑变性的变化。采用一系列体外和体内研究在啮齿动物和人类中，我们建议验证在地形上测量外部视网膜RPE的方案以及BM形态，光化和黑色素密度以及光感受器功能。我们将验证和测试这些结构和功能测量的可重复性，并将其应用于研究与年龄相关的变化在正常受试者的横截面中。最后，我们将进行试验临床成像研究，首先进行比较衰老到早期的AMD，其次，确定候选早期生物标志物，以使drusen向萎缩发展。如果成功，该提案将为更广泛的纵向研究奠定基础，以研究AMD 人类视网膜和新生物标志物的行业发展为临床试验。